Last reviewed · How we verify
Atezolizumab and Recombinant Human Hyaluronidase
Atezolizumab and Recombinant Human Hyaluronidase is a PD-L1 inhibitor Biologic drug developed by National Cancer Institute (NCI). It is currently in Phase 3 development for Non-small cell lung cancer (NSCLC), Urothelial carcinoma, Triple-negative breast cancer. Also known as: Atezolizumab + rHuPH20, Atezolizumab and Hyaluronidase, Atezolizumab and Hyaluronidase-tqjs, Atezolizumab and Recombinant Human Hyaluronidase-tqjs.
Atezolizumab is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with recombinant human hyaluronidase to enhance subcutaneous delivery and bioavailability.
Atezolizumab is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with recombinant human hyaluronidase to enhance subcutaneous delivery and bioavailability. Used for Non-small cell lung cancer (NSCLC), Urothelial carcinoma, Triple-negative breast cancer.
At a glance
| Generic name | Atezolizumab and Recombinant Human Hyaluronidase |
|---|---|
| Also known as | Atezolizumab + rHuPH20, Atezolizumab and Hyaluronidase, Atezolizumab and Hyaluronidase-tqjs, Atezolizumab and Recombinant Human Hyaluronidase-tqjs, Atezolizumab with rHuPH20 |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Atezolizumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 and restoring anti-tumor T-cell immunity. The addition of recombinant human hyaluronidase (rHuPH20) degrades hyaluronic acid in subcutaneous tissue, enabling faster absorption and improved pharmacokinetics of the antibody when administered subcutaneously rather than intravenously.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Triple-negative breast cancer
- Other solid tumors in phase 3 development
Common side effects
- Fatigue
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Injection site reactions
Key clinical trials
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (PHASE3)
- Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer (PHASE2)
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (PHASE1, PHASE2)
- A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- SMMART Adaptive Clinical Treatment (ACT) Trial (EARLY_PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (PHASE1)
- Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atezolizumab and Recombinant Human Hyaluronidase CI brief — competitive landscape report
- Atezolizumab and Recombinant Human Hyaluronidase updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about Atezolizumab and Recombinant Human Hyaluronidase
What is Atezolizumab and Recombinant Human Hyaluronidase?
How does Atezolizumab and Recombinant Human Hyaluronidase work?
What is Atezolizumab and Recombinant Human Hyaluronidase used for?
Who makes Atezolizumab and Recombinant Human Hyaluronidase?
Is Atezolizumab and Recombinant Human Hyaluronidase also known as anything else?
What drug class is Atezolizumab and Recombinant Human Hyaluronidase in?
What development phase is Atezolizumab and Recombinant Human Hyaluronidase in?
What are the side effects of Atezolizumab and Recombinant Human Hyaluronidase?
What does Atezolizumab and Recombinant Human Hyaluronidase target?
Related
- Drug class: All PD-L1 inhibitor drugs
- Target: All drugs targeting PD-L1
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (NSCLC)
- Indication: Drugs for Urothelial carcinoma
- Indication: Drugs for Triple-negative breast cancer
- Also known as: Atezolizumab + rHuPH20, Atezolizumab and Hyaluronidase, Atezolizumab and Hyaluronidase-tqjs, Atezolizumab and Recombinant Human Hyaluronidase-tqjs, Atezolizumab with rHuPH20